Citigroup Cuts ICON Public (NASDAQ:ICLR) Price Target to $290.00

ICON Public (NASDAQ:ICLR) had its price target trimmed by Citigroup from $300.00 to $290.00 in a report issued on Monday,Benzinga reports. The firm currently has a buy rating on the medical research company’s stock.

Several other research analysts have also recently issued reports on ICLR. Truist Financial reaffirmed a “buy” rating and set a $284.00 price objective (down from $295.00) on shares of ICON Public in a research report on Wednesday, December 18th. TD Cowen dropped their price target on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Leerink Partners restated an “outperform” rating and set a $255.00 price objective (down previously from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Leerink Partnrs upgraded shares of ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. Finally, StockNews.com cut shares of ICON Public from a “buy” rating to a “hold” rating in a research report on Thursday, September 19th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $287.00.

ICON Public Stock Performance

Shares of ICON Public stock opened at $219.34 on Monday. The business has a 50-day simple moving average of $211.42 and a 200-day simple moving average of $273.13. The company has a market cap of $18.09 billion, a PE ratio of 24.45, a P/E/G ratio of 1.54 and a beta of 1.20. ICON Public has a one year low of $183.38 and a one year high of $347.72. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the prior year, the company posted $3.10 earnings per share. On average, equities research analysts forecast that ICON Public will post 13.42 EPS for the current fiscal year.

Institutional Investors Weigh In On ICON Public

Large investors have recently modified their holdings of the stock. Ashton Thomas Private Wealth LLC purchased a new position in ICON Public in the 2nd quarter valued at $54,000. GAMMA Investing LLC boosted its holdings in shares of ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of ICON Public by 39.2% during the second quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock worth $129,000 after acquiring an additional 111 shares during the period. Whittier Trust Co. of Nevada Inc. raised its holdings in ICON Public by 23.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after purchasing an additional 96 shares in the last quarter. Finally, First Horizon Advisors Inc. lifted its position in ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 151 shares during the period. Hedge funds and other institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.